the model is robust to a wide range of parameter estimates. CONCLUSIONS: This analysis suggests that the use of ATVϩRTV in the Mexican healthcare setting is a preferred option when compared to LPVϩRTV for treatment of treatment-naïve HIV patients. 
PIN25

COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF THE VARICELLA VACCINE IN COLOMBIA
De la Hoz F 
OBJECTIVES:
To perform a cost-effectiveness analysis of the introduction of the varicella vaccine in the National Immunization Program of Colombia. METHODS: A decision analysis model was built to follow two cohorts from birth. One cohort had vaccination, and the other did not. The time horizon was 30 years. The perspective was from the third payer. A micro-costing assessment of varicella in Colombia was undertaken. All costs were expressed in 2008 dollars of December 31. Incremental cost-effectiveness ratio (ICER) was the main outcome measure. A discount rate for health benefits and costs of 3% was used. A sensitivity analysis was made to assess assumptions uncertainty. RESULTS: Vaccination would avoid 9,415,444 consultations, 17,576 hospitalizations, and 1,144 varicella deaths. Cost per Life-Year Gained (LYG) was US$2,527/LYG. From the third payer perspective in Colombia, varicella costs without vaccination would be US$88 millions, and with vaccination US$35 million. The sensitivity analysis shows that the vaccination strategy is not costeffective if vaccination cost per dose is higher than US$15.6. In the case of a booster dose every ten years, the vaccination would not be cost-effective if vaccination cost per dose is higher than US$9.8. CONCLUSIONS: Varicella vaccination is highly cost-effective according to World Health Organization criteria (less than per capita gross domestic product). The authors recommend, weighting the budget impact, the implementation of the varicella vaccine in Colombia. 
PIN26 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF BACTEREMIA AND INFECTIVE ENDOCARDITIS IN PATIENTS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION IN MEXICO
OBJECTIVES:
The recent increase of methicillin-resistant S. aureus (MRSA) as the leading cause of bacteremia, and subsequent infective endocarditis, has led clinicians to resort to alternative treatments, rather than the traditional penicillinbased treatment strategy. Such alternatives include daptomycin, which has proven to be efficacious. An economic evaluation was performed to determine the most cost-effective alternative between daptomycin and vancomycin for the treatment of patients with MRSA bacteremia and infective endocarditis. METHODS: A costeffectiveness analysis was performed from an institutional perspective (Mexican Institute of Social Security, IMSS). Vancomycin is currently the treatment of choice for infective endocarditis within the treatment guidelines; daptomycin is regarded as an alternative treatment. Effectiveness and safety data was taken from published literature; effectiveness parameters included clinical and bacteriological cure, and safety parameters included drug-related adverse events. Resource use data was obtained from the institution; total direct costs of hospitalization and treatment were considered. The source of the unit costs was the institution, current for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount rate was used. A decision tree was built with three possible outcomes considered: success or failure to treatment, and death. A probabilistic sensitivity analysis was performed through a Monte Carlo simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS:
The results show a cost/effectiveness ratio of $371,813.80 MXP for daptomycin compared to $466,229.23 MXP for vancomycin, making daptomycin a more cost-effective alternative (dominant) for the treatment of bacteremia and infective endocarditis. CONCLUSIONS: From an institutional perspective in Mexico, daptomycin is a more cost-effective (dominant) alternative than vancomycin for the treatment of bacteremia and infective endocarditis in patients with MRSA infection. 
PIN27 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF ACELLULAR PERTUSSIS IN COLOMBIAN ADOLESCENTS
OBJECTIVES:
The loss of vaccine-induced immunity to pertussis over ten years after administered increment the burden of pertussis-related disease. To diminish the burden of pertussis-related disease on children under-5 years we propose a cost-effectiveness analysis of the introduction of pertussis vaccine in Colombian adolescents. METHODS: Two cohorts (with vaccinated and unvaccinated adolescents) of children were followed from birth to 5 years (both vaccinated with current scheme: 2-4-6-18 months and 5 years with DTwP). A decision model was used to estimate the burden of pertussis-related disease. The cost of pertussis was taken from a previous study. A government perspective was used. Vaccine administration cost plus vaccine price were assumed between US$5-US$12 per dose. Adolescent vaccination coverage was assumed to be 70%. A deterministic sensitivity analysis was performed. Costs were US dollars from 2008. RESULTS: Without adolescents vaccination, the current scheme reduce 93% pertussis cases (from 102,196 to 6,912), 83% deaths (from 408 to 55), and 93% DALYs (18,189 to 1,233). With adolescent vaccination, cases would reduce from 6,912 to 4,838, deaths from 408 to 39, and DALYs from 1,233 to 860, in the current scenario. Total pertussis costs without adolescent vaccination is US$737,186, and with vaccination US$516,030. Incremental Cost-Effectiveness Ratio with a vaccination coverage of 70% would go from 4,188 (vaccination cost per dose: US$5) to 10,331 (vaccination cost per dose: US$12). CONCLUSIONS: This is the first study in a developing country that assesses pertussis vaccination in adolescent. Pertussis adolescent vaccination was cost-effective in Colombia, according to World Health Organization criteria (less than three times the per-capita Gross Domestic Product). The investigators recommend adolescents pertussis vaccination in Colombia. 
PIN28 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES
OBJECTIVES:
The quadrivalent (6, 11, 16, 18) HPV vaccine has been approved in Brazil for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital warts in women age 9 to 26 years. We assessed the health and economic impact of the quadrivalent (6, 11, 16, 18) HPV vaccine from the healthcare system perspective in Brazil. METHODS: A published mathematical model of the transmission dynamics of HPV infection and disease was adapted for Brazil. Model inputs were used from Brazil or the Latin/America region when available; otherwise, the default values in the original model were used. Maintaining current cervical cancer screening practices in Brazil, we evaluated two strategies: routine vaccination of females by age 12 (S1), and S1 combined with a temporary (5 years) female catch-up program for age 12-24 years (S2). The vaccine coverage rates were 85% for the routine and 50% for the catch-up vaccination programs. RESULTS: The most effective strategy was S2. Comparing S2 to no vaccination, we estimated the cumulative percent reduction in incident HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases would be 81%, 57%, 70%, 72%, and 59%, respectively over 100 years. The cost-effectiveness ratios were Brazil Reals 1,203 (US$ 699) per quality-adjusted life years (QALY) gained for S1 compared with no vaccination, and Brazil Reals 1,522 (US$ 885) per QALY gained for S2 compared with S1. CONCLUSIONS: In Brazil, vaccination of females age 12-24 years with a quadrivalent (6,11,16,18) HPV vaccine can reduce the incidence of cervical cancer, CIN, and genital warts at a cost per QALY ratio within the range typically regarded by the World Health Organization as costeffective.
PIN29 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH FAILURE TO VANCOMYCIN THERAPY IN MEXICO
Briones B 1 , Martinez Revelles M 1 , García-Contreras F proved to be efficacious in the management of SSTI. An economic evaluation was performed to determine the most cost-effective alternative between daptomycin and linezolid for the treatment of SSTI with failure to vancomycin therapy. METHODS: A cost-effectiveness analysis was performed from an institutional perspective (Mexican Institute of Social Security, IMSS). Both drugs are included within the treatment guidelines as secondary therapy for SSTI following vancomycin failure. As required per guidelines, use of concomitant therapy with ciprofloxacin and metronidazole was also considered. Effectiveness and safety data was taken from published literature; effectiveness parameters included clinical and microbiological cure, and safety parameters included drug-related adverse events. Resource use data was obtained from the institution; total direct costs of hospitalization and treatment were considered. The source of the unit costs was the institution, current for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount rate was used. A decision tree was built, considering two possible outcomes: success and failure to treatment. A probabilistic sensitivity analysis was performed through a Monte Carlo simulation with 100,000 iterations to confirm the robustness of the model. RESULTS: The results show a cost/effectiveness ratio of $52,135.67 MXP for daptomycin compared to $67,623.14 MXP for linezolid, making daptomycin a more cost-effective alternative (dominant) for the treatment of SSTI. The sensitivity analysis confirmed the robustness of the model. CONCLUSIONS: From an institutional perspective in Mexico, daptomycin is a more cost-effective (dominant) alternative than linezolid for the treatment of SSTI in patients that failed treatment with vancomycin. 
PIN30 COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAÏVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO
OBJECTIVES:
To evaluate the cost effectiveness analysis of Efavirenz/Emtricitabine/Tenofovir ((TDFϩFTCϩEFV) in naïve patients with HIV from the public health system Mexican perspective. METHODS: A decision tree model was developed to estimate the efficacy and expected value of direct medical costs. Efficacy was measured by the percentage of individuals with plasma HIV RNA Ͻ 50 copies/mL and and Ͻ 400 copies/mL. at 96 weeks, based on a systematic review and meta-analysis of clinical trials of regimens in treatment-naïve populations. Model follows the recommendations of antiretroviral persons handling Guide with HIV in Mexico (2009 SSA). The direct costs and treatment of adverse events in the treatment of HIV were estimated. When the patient failure, the cost of new treatment was added. The unitary costs were obtained from the Mexican public health institutions. All costs were calculated in 2010 Mexican Pesos (MXP). Incremental-costeffectiveness-ratios were expressed as cost per 1% of individuals with plasma HIV RNA Ͻ 50 copies/mL and and Ͻ 400 copies/mL Costs and outcomes were discounted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were undertaken to incorporate likely distributional properties of key model. RESULTS: EFVϩFTCϩTDF was most effective than others comparators with probability of 0.734 (CI95%:0.601-0.835; nϭ514) -except when compare with TDF/FTC ϩ ATV/r with efficacy of 0.743 CI95%:0. 700-0.786; nϭ440-and 0.746 (0.686-0.798; nϭ232) of having Ͻ50 or Ͻ400 RNA copies/ml respectively at 96 weeks, EFVϩFTCϩTDF resulted as the alternative with less unitary average total cost ($60, 026.00 MX and $60, 122.00, respectively) . TDF/FTC/EFV combination is a dominant option and cost saving compared to alternatives, except TDF/FTC ϩ ATV/r (cost per 1% of individuals with plasma HIV RNA Ͻ 50 copies/mL of $8,490,581).Deterministic and probabilistic sensitivity analysis showed that the findings are robust. CONCLUSIONS: Efavirenz/Emtricitabine/Tenofovir is a cost effective drug on 96 weeks for the treatment of adult naïve patients with HIV infection in Mexico. [NoTx] ) in healthy adults with influenza-like symptoms who visit physicians within or beyond 48 hours of the onset of symptoms. METHODS: A decision model was created to predict total and direct medical costs, symptom-free days, quality of life and days of work lost within 14 days from the perspective of patients. Most model inputs were derived from the literature; some were obtained from internal data and expert opinions. Total costs (in $2009 USD) included costs associated with prescriptions/OTC, tests, complications, hospitalization and work-day loss. Cost-effectiveness analysis, cost-utility analysis and probabilistic sensitivity analysis were performed. RESULTS: Total costs per symptom-free day were $119 ($874/7. costs per symptom-free day were $46, $25, $57, $49, $60 and $$46 for Universal, NoTx, Standard, POCT, Emiric_Lab and Empiric, respectively. Direct medical costs per quality of life were $425, $311, $755, $594, $639 and $$360 for Universal, NoTx, Standard, POCT, Emiric_Lab and Empiric, respectively. Sensitivity analysis indicated the study results were robust. CONCLUSIONS: With consideration of total costs, the universal option was the most cost-effective option. With consideration of direct medical costs only, no treatment is the most cost-effective option.
PIN31 COST-EFFECTIVENESS ANALYSIS OF DIFFERENT APPROACHES TO THE DIAGNOSIS AND TREATMENT OF INFLUENZA-LIKE ILLNESS IN HEALTHY ADULTS
PIN32 PHARMACOECONOMIC ANALYSIS OF MARAVIROC IN TREATMENT-EXPERIENCED HIV PATIENTS IN BRAZIL
